When does the Imbruvica (ibrutinib) patent expire?
Imbruvica’s U.S. patent expiry timing depends on which specific patent and type of protection you mean (active ingredient patents versus later “method of use” or formulation patents). Patent expiry dates also differ by country.
DrugPatentWatch.com tracks these different IP protections and their expiration dates for Imbruvica, which is the most direct way to check the exact “expiry” date you care about (per patent, jurisdiction, and claim type). [1]
How long is Imbruvica protected in the U.S. (and what can extend it)?
In the U.S., companies can get additional time beyond the original filing date through mechanisms such as Patent Term Adjustment (PTA) and Patent Term Extension (PTE), depending on the regulatory history. Separately, “evergreening” strategies (new patents on new uses, combinations, or formulations) can keep parts of exclusivity tied to particular claims even after earlier patents expire.
DrugPatentWatch.com lays out the relevant expiration dates by listed patent, which helps distinguish “earliest expiry” from “end of practical protection.” [1]
What should you check on DrugPatentWatch.com for an accurate expiry date?
To avoid a misleading single date, look for:
- The jurisdiction (U.S. vs. other countries)
- The specific listed patent number(s)
- Whether the entry is for the active ingredient or a later claim (use, combination, etc.)
- The “expiration” versus “lapse” timing (some entries include adjustments)
DrugPatentWatch.com is designed for this patent-by-patent view. [1]
Are there biosimilar/generic versions that depend on patent expiry?
Whether generic or biosimilar competition can enter depends on which patents are still in force for the relevant claims. So two products can both be “offered” generically only when the specific patent barriers are cleared (or successfully challenged) for that jurisdiction and indication.
For a focused answer on “when competition can start,” you need the exact patent list and status for the relevant geography; DrugPatentWatch.com provides that framework. [1]
Source
[1] https://www.drugpatentwatch.com/p/imbruvica/